Clinical risk scores such as CHA2DS2-VASc and HAS-BLED offer modest but practical predictive value for stroke and bleeding in atrial fibrillation, requiring dynamic reassessment over time.
Clinical risk scores like CHA2DS2-VASc and HAS-BLED, while having modest predictive ability, remain essential practical tools for dynamic stroke and bleeding risk assessment in AF patients.
Optimal stroke prevention using oral anticoagulant (OAC) therapy is essential for the management of patients with atrial fibrillation (AF) who are at increased risk of stroke, but decision making on thromboprophylaxis requires evaluation of individual patient's thromboembolic and bleeding risks.1 Several risk assessment tools have been developed to streamline the evaluation of patients with AF but navigating through the labyrinth of options may be confusing for clinicians.2
Proietti et al. (2018) conducted an editorial in Atrial Fibrillation. Stroke and bleeding risk assessment tools was evaluated. Clinical risk scores such as CHA2DS2-VASc and HAS-BLED offer modest but practical predictive value for stroke and bleeding in atrial fibrillation, requiring dynamic reassessment over time.